Trade Achieve Life Sciences, Inc. - ACHV CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.27 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.024068% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.001846% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 4.87 |
| Open* | 4.88 |
| 1-Year Change* | -1.21% |
| Day's Range* | 4.79 - 4.95 |
| 52 wk Range | 2.00-8.13 |
| Average Volume (10 days) | 105.82K |
| Average Volume (3 months) | 2.12M |
| Market Cap | 77.85M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 17.93M |
| Revenue | N/A |
| EPS | -3.99 |
| Dividend (Yield %) | N/A |
| Beta | 1.46 |
| Next Earnings Date | May 10, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 4.91 | 0.03 | 0.61% | 4.88 | 4.95 | 4.79 |
| Jun 28, 2022 | 4.87 | -0.23 | -4.51% | 5.10 | 5.20 | 4.85 |
| Jun 27, 2022 | 5.10 | 0.02 | 0.39% | 5.08 | 5.14 | 4.91 |
| Jun 24, 2022 | 5.15 | 0.05 | 0.98% | 5.10 | 5.24 | 5.00 |
| Jun 23, 2022 | 5.06 | -0.08 | -1.56% | 5.14 | 5.32 | 5.06 |
| Jun 22, 2022 | 5.12 | 0.03 | 0.59% | 5.09 | 5.37 | 5.09 |
| Jun 21, 2022 | 5.29 | -0.24 | -4.34% | 5.53 | 5.63 | 5.28 |
| Jun 17, 2022 | 5.49 | 0.01 | 0.18% | 5.48 | 5.69 | 5.34 |
| Jun 16, 2022 | 5.48 | -0.35 | -6.00% | 5.83 | 5.83 | 5.45 |
| Jun 15, 2022 | 5.90 | -0.05 | -0.84% | 5.95 | 6.07 | 5.82 |
| Jun 14, 2022 | 5.94 | -0.13 | -2.14% | 6.07 | 6.12 | 5.87 |
| Jun 13, 2022 | 5.99 | -0.22 | -3.54% | 6.21 | 6.25 | 5.92 |
| Jun 10, 2022 | 6.39 | -0.16 | -2.44% | 6.55 | 6.55 | 6.39 |
| Jun 9, 2022 | 6.57 | 0.06 | 0.92% | 6.51 | 6.63 | 6.51 |
| Jun 8, 2022 | 6.58 | 0.19 | 2.97% | 6.39 | 6.60 | 6.39 |
| Jun 7, 2022 | 6.55 | 0.09 | 1.39% | 6.46 | 6.62 | 6.39 |
| Jun 6, 2022 | 6.47 | -0.14 | -2.12% | 6.61 | 6.71 | 6.46 |
| Jun 3, 2022 | 6.63 | -0.03 | -0.45% | 6.66 | 6.74 | 6.56 |
| Jun 2, 2022 | 6.60 | 0.04 | 0.61% | 6.56 | 6.63 | 6.56 |
| Jun 1, 2022 | 6.54 | -0.23 | -3.40% | 6.77 | 6.80 | 6.42 |
Achieve Life Sciences, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 5.062 | 0 | 0 | 0 | 0 | 0 |
| Revenue | 5.062 | |||||
| Total Operating Expense | 26.254 | 5.16 | 12.813 | 16.528 | 14.75 | 33.094 |
| Selling/General/Admin. Expenses, Total | 8.933 | 3.531 | 6.945 | 6.854 | 7.868 | 9.128 |
| Research & Development | 14.788 | 3.101 | 5.868 | 9.674 | 6.882 | 23.966 |
| Unusual Expense (Income) | 2.533 | -1.472 | 0 | 0 | ||
| Operating Income | -21.192 | -5.16 | -12.813 | -16.528 | -14.75 | -33.094 |
| Interest Income (Expense), Net Non-Operating | 0.203 | 0.021 | 0.171 | 0.17 | 0.069 | 0.017 |
| Other, Net | 0.86 | 0.115 | -0.045 | -0.037 | -0.049 | -0.075 |
| Net Income Before Taxes | -20.129 | -13.634 | -12.687 | -16.395 | -14.73 | -33.152 |
| Net Income After Taxes | -20.129 | -10.583 | -12.687 | -16.395 | -14.73 | -33.152 |
| Net Income Before Extra. Items | -20.129 | -10.583 | -12.687 | -16.395 | -14.73 | -33.152 |
| Net Income | -20.129 | -10.583 | -12.687 | -16.395 | -14.73 | -33.152 |
| Income Available to Common Excl. Extra. Items | -20.129 | -10.583 | -12.687 | -16.395 | -14.73 | -33.152 |
| Income Available to Common Incl. Extra. Items | -20.129 | -10.583 | -12.687 | -16.395 | -14.73 | -33.152 |
| Diluted Net Income | -20.129 | -10.583 | -12.687 | -16.395 | -14.73 | -33.152 |
| Diluted Weighted Average Shares | 0.01361 | 0.02397 | 0.17551 | 0.41232 | 2.71891 | 8.11984 |
| Diluted EPS Excluding Extraordinary Items | -1478.62 | -441.473 | -72.2861 | -39.7628 | -5.41761 | -4.08284 |
| Diluted Normalized EPS | -1292.55 | -247.927 | -72.2861 | -39.7628 | -5.41761 | -4.08284 |
| Gain (Loss) on Sale of Assets | -8.61 | 0 | 0 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 7.984 | 11.302 | 6.693 | 7.115 | 7.226 |
| Selling/General/Admin. Expenses, Total | 2.342 | 2.075 | 2.102 | 2.609 | 2.838 |
| Research & Development | 5.642 | 9.227 | 4.591 | 4.506 | 4.388 |
| Operating Income | -7.984 | -11.302 | -6.693 | -7.115 | -7.226 |
| Interest Income (Expense), Net Non-Operating | 0.008 | 0.003 | 0.003 | 0.003 | -0.353 |
| Other, Net | -0.023 | -0.012 | -0.001 | -0.039 | 0.006 |
| Net Income Before Taxes | -7.999 | -11.311 | -6.691 | -7.151 | -7.573 |
| Net Income After Taxes | -7.999 | -11.311 | -6.691 | -7.151 | -7.573 |
| Net Income Before Extra. Items | -7.999 | -11.311 | -6.691 | -7.151 | -7.573 |
| Net Income | -7.999 | -11.311 | -6.691 | -7.151 | -7.573 |
| Income Available to Common Excl. Extra. Items | -7.999 | -11.311 | -6.691 | -7.151 | -7.573 |
| Income Available to Common Incl. Extra. Items | -7.999 | -11.311 | -6.691 | -7.151 | -7.573 |
| Diluted Net Income | -7.999 | -11.311 | -6.691 | -7.151 | -7.573 |
| Diluted Weighted Average Shares | 6.13182 | 7.3906 | 9.45224 | 9.4682 | 9.45875 |
| Diluted EPS Excluding Extraordinary Items | -1.30451 | -1.53046 | -0.70787 | -0.75527 | -0.80063 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.30451 | -1.53046 | -0.70787 | -0.75527 | -0.80063 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 26.927 | 5.908 | 15.537 | 17.334 | 36.975 | 44.594 |
| Cash and Short Term Investments | 25.463 | 5.284 | 14.604 | 16.664 | 35.853 | 43.022 |
| Cash | 1.8 | |||||
| Cash & Equivalents | 11.931 | 5.284 | 9.515 | 16.664 | 35.853 | 43.022 |
| Short Term Investments | 11.732 | 5.089 | ||||
| Total Receivables, Net | 0.51 | 0.009 | 0.007 | 0.008 | 0.153 | |
| Accounts Receivable - Trade, Net | 0.478 | 0.009 | 0.007 | 0.008 | ||
| Prepaid Expenses | 0.954 | 0.393 | 0.926 | 0.662 | 1.122 | 1.419 |
| Total Assets | 27.47 | 9.892 | 19.084 | 21.078 | 40.298 | 47.516 |
| Property/Plant/Equipment, Total - Net | 0.258 | 0.059 | 0.035 | 0.386 | 0.188 | 0.079 |
| Property/Plant/Equipment, Total - Gross | 1.707 | 1.144 | 0.755 | 0.986 | 0.82 | 0.366 |
| Accumulated Depreciation, Total | -1.449 | -1.085 | -0.72 | -0.6 | -0.632 | -0.287 |
| Other Long Term Assets, Total | 0.285 | 0.359 | 0.168 | 0.237 | 0.237 | 0.168 |
| Total Current Liabilities | 8.455 | 2.013 | 3.27 | 2.869 | 2.935 | 4.55 |
| Accounts Payable | 2.121 | 0.213 | 0.144 | 0.859 | 0.332 | 0.841 |
| Accrued Expenses | 6.045 | 1.773 | 3.126 | 2.01 | 2.603 | 3.709 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.057 | 0.027 | ||||
| Other Current Liabilities, Total | 0.232 | 0 | ||||
| Total Liabilities | 8.504 | 2.013 | 3.282 | 3.028 | 3.012 | 19.474 |
| Total Long Term Debt | 0.049 | 0 | 0 | 0 | 0 | 14.92 |
| Long Term Debt | 0.049 | 14.92 | ||||
| Total Equity | 18.966 | 7.879 | 15.802 | 18.05 | 37.286 | 28.042 |
| Common Stock | 0.029 | 0.012 | 0.018 | 0.041 | 0.076 | 0.079 |
| Additional Paid-In Capital | 213.239 | 20.556 | 41.161 | 63.709 | 97.64 | 121.545 |
| Retained Earnings (Accumulated Deficit) | -196.942 | -12.694 | -25.381 | -45.704 | -60.434 | -93.586 |
| Other Equity, Total | 2.64 | 0.005 | 0.004 | 0.004 | 0.004 | 0.004 |
| Total Liabilities & Shareholders’ Equity | 27.47 | 9.892 | 19.084 | 21.078 | 40.298 | 47.516 |
| Total Common Shares Outstanding | 0.01365 | 0.05978 | 0.33606 | 1.47426 | 6.11174 | 9.45354 |
| Other Current Assets, Total | 0.222 | 0 | ||||
| Goodwill, Net | 1.034 | 1.034 | 1.034 | 1.034 | 1.034 | |
| Intangibles, Net | 2.532 | 2.31 | 2.087 | 1.864 | 1.641 | |
| Deferred Income Tax | 0 | |||||
| Other Liabilities, Total | 0.012 | 0.159 | 0.077 | 0.004 | ||
| Total Preferred Shares Outstanding | 0.00058 | 0.00112 | 0 | |||
| Redeemable Preferred Stock | 0 | 0 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 30.439 | 42.431 | 34.733 | 44.594 | 37.692 |
| Cash and Short Term Investments | 29.637 | 42.001 | 33.312 | 43.022 | 36.337 |
| Cash & Equivalents | 29.637 | 42.001 | 33.312 | 43.022 | 36.337 |
| Prepaid Expenses | 0.802 | 0.43 | 1.27 | 1.419 | 1.355 |
| Total Assets | 33.662 | 45.565 | 37.799 | 47.516 | 40.614 |
| Property/Plant/Equipment, Total - Net | 0.141 | 0.121 | 0.1 | 0.079 | 0.049 |
| Goodwill, Net | 1.034 | 1.034 | 1.034 | 1.034 | 1.034 |
| Intangibles, Net | 1.809 | 1.752 | 1.697 | 1.641 | 1.586 |
| Other Long Term Assets, Total | 0.239 | 0.227 | 0.235 | 0.168 | 0.253 |
| Total Current Liabilities | 3.515 | 4.67 | 3.076 | 4.55 | 4.01 |
| Accounts Payable | 0.585 | 0.575 | 0.815 | 0.841 | 0.418 |
| Accrued Expenses | 2.93 | 4.095 | 2.261 | 3.709 | 3.592 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.574 | 4.711 | 3.099 | 19.474 | 19.181 |
| Total Long Term Debt | 0 | 0 | 0 | 14.92 | 15.171 |
| Other Liabilities, Total | 0.059 | 0.041 | 0.023 | 0.004 | 0 |
| Total Equity | 30.088 | 40.854 | 34.7 | 28.042 | 21.433 |
| Redeemable Preferred Stock | 0 | ||||
| Common Stock | 0.076 | 0.079 | 0.079 | 0.079 | 0.079 |
| Additional Paid-In Capital | 98.441 | 120.515 | 121.052 | 121.545 | 122.509 |
| Retained Earnings (Accumulated Deficit) | -68.433 | -79.744 | -86.435 | -93.586 | -101.159 |
| Other Equity, Total | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| Total Liabilities & Shareholders’ Equity | 33.662 | 45.565 | 37.799 | 47.516 | 40.614 |
| Total Common Shares Outstanding | 6.14992 | 9.45222 | 9.45354 | 9.45354 | 9.47358 |
| Total Preferred Shares Outstanding | 0 | 0 | |||
| Total Receivables, Net | 0.151 | 0.153 | 0 | ||
| Long Term Debt | 14.92 | 15.171 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -20.129 | -10.583 | -12.687 | -16.395 | -14.73 | -33.152 |
| Cash From Operating Activities | -29.683 | -9.107 | -10.623 | -15.216 | -13.474 | -29.44 |
| Cash From Operating Activities | 0.188 | 0.059 | 0.06 | 0.031 | 0.032 | 0.027 |
| Non-Cash Items | 0.978 | 7.336 | 0.854 | 1.198 | 1.286 | 2.228 |
| Changes in Working Capital | -10.72 | -3.091 | 0.928 | -0.273 | -0.285 | 1.234 |
| Cash From Investing Activities | 10.608 | 12.648 | -5.125 | 5.036 | -0.017 | |
| Capital Expenditures | -0.046 | -0.046 | -0.053 | -0.017 | ||
| Other Investing Cash Flow Items, Total | 10.654 | 12.648 | -5.079 | 5.089 | ||
| Cash From Financing Activities | -0.002 | 2.001 | 19.757 | 17.325 | 32.68 | 36.61 |
| Financing Cash Flow Items | -0.002 | 1.937 | 4.96 | 12.334 | 27.87 | |
| Issuance (Retirement) of Stock, Net | 0 | 0.064 | 14.797 | 4.991 | 4.81 | 21.681 |
| Foreign Exchange Effects | 0 | -0.001 | 0 | 0.004 | -0.001 | |
| Net Change in Cash | -19.077 | 5.541 | 4.009 | 7.149 | 19.189 | 7.169 |
| Amortization | 0.223 | 0.222 | 0.223 | 0.223 | 0.223 | |
| Deferred Taxes | -3.051 | |||||
| Issuance (Retirement) of Debt, Net | 0 | 14.929 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -7.999 | -19.31 | -26.001 | -33.152 | -7.573 |
| Cash From Operating Activities | -6.452 | -15.528 | -24.222 | -29.44 | -6.779 |
| Cash From Operating Activities | 0.064 | 0.127 | 0.188 | 0.25 | |
| Non-Cash Items | 0.565 | 1.204 | 1.734 | 2.228 | 1.12 |
| Changes in Working Capital | 0.918 | 2.451 | -0.143 | 1.234 | -0.386 |
| Cash From Investing Activities | 0 | 0 | 0 | ||
| Capital Expenditures | 0 | 0 | 0 | ||
| Cash From Financing Activities | 0.236 | 21.674 | 21.682 | 36.61 | 0.095 |
| Issuance (Retirement) of Stock, Net | 0.236 | 21.674 | 21.682 | 21.681 | 0.024 |
| Net Change in Cash | -6.216 | 6.148 | -2.541 | 7.169 | -6.685 |
| Financing Cash Flow Items | 0 | 0 | 0.071 | ||
| Foreign Exchange Effects | 0.002 | -0.001 | -0.001 | -0.001 | |
| Issuance (Retirement) of Debt, Net | 14.929 | ||||
| Amortization | 0.06 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| B. Riley Asset Management, LLC | Investment Advisor/Hedge Fund | 19.4865 | 3494000 | 0 | 2023-03-01 | MED |
| Contrarian Alpha Management, L.L.C. | Corporation | 7.6288 | 1367873 | 1367873 | 2022-11-18 | |
| Francis Capital Management, LLC | Hedge Fund | 2.4117 | 432432 | -161818 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.8976 | 340238 | -8075 | 2022-12-31 | LOW |
| Shay Capital LLC | Hedge Fund | 1.8962 | 340000 | 0 | 2022-12-31 | HIGH |
| Long Focus Capital Management LLC | Hedge Fund | 1.7469 | 313220 | 5000 | 2022-12-31 | MED |
| Perkins Capital Management, Inc. | Investment Advisor | 1.2164 | 218100 | 0 | 2022-12-31 | LOW |
| LPL Financial LLC | Investment Advisor | 0.8271 | 148300 | 48400 | 2022-12-31 | LOW |
| Wells Fargo Advisors | Research Firm | 0.7022 | 125910 | -12000 | 2022-12-31 | LOW |
| Raymond James & Associates, Inc. | Research Firm | 0.4978 | 89249 | 71818 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.4761 | 85365 | -189 | 2022-12-31 | LOW |
| Fichthorn (John) | Individual Investor | 0.3067 | 55000 | 0 | 2023-03-01 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.283 | 50746 | 15746 | 2022-12-31 | HIGH |
| Group One Trading, L.P. | Research Firm | 0.2751 | 49322 | 6861 | 2022-12-31 | HIGH |
| Renaissance Technologies LLC | Hedge Fund | 0.2186 | 39200 | 500 | 2022-12-31 | HIGH |
| Bencich (John A.) | Individual Investor | 0.2059 | 36920 | 22000 | 2022-11-18 | MED |
| Diametric Capital | Investment Advisor/Hedge Fund | 0.1933 | 34660 | 15153 | 2022-09-30 | HIGH |
| QS Investors, LLC | Investment Advisor/Hedge Fund | 0.1899 | 34050 | 33500 | 2021-06-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.1697 | 30422 | 30422 | 2022-12-31 | HIGH |
| Clearline Capital LP | Hedge Fund | 0.1515 | 27156 | -92938 | 2022-12-31 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Achieve Life Sciences, Inc. Company profile
About Achieve Life Sciences Inc
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. It is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Achieve Life Sciences Inc revenues was not reported. Net loss increased from $14.7M to $33.2M. Higher net loss reflects Research & Development increase from $6.5M to $23.3M (expense), General & Administrative increase of 9% to $7.6M (expense), General and administrative increase of 70% to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$5.42 to -$4.08.
Equity composition
Common Stock $.001 Par, 04/11, 25M auth., 9,718,251 issd. Insiders own 4.45%. IPO: 10/95, 3,063,750 shares @ $7 by Hambrecht & Quist. *NOTE: All Preferred Stock converted to Common upon completion of IPO. 08/08, Name changed from Sonus Pharmaceuticals, Inc. 08/08, 1-for-18, reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
22722 29Th Dr. Se
Suite 100
SEATTLE
WASHINGTON 98021
US
Income Statement
- Annual
- Quarterly
News
Ripple/SEC Lawsuit: News And Update
Ripple and the US Securities and Exchange Commission are still awaiting a ruling
15:14, 20 March 2023
S&P 500 holds its ground after banking rout ahead of FOMC meeting
Equity indices recover some momentum after the bailout of Credit Suisse
09:07, 17 March 2023
GBP/USD latest: US CPI, UK spring budget, banking shares rout
GBP/USD runs into resistance after a three-day rally as risk appetite shifts
14:07, 15 March 2023
What now after US jobs data? - FX, Equities, Commodities outlook
Markets reacted to a mixed jobs reading in the US as traders look ahead to this month's FOMC meeting
14:06, 10 March 2023
EXCLUSIVE-BlackRock fast-tracks eviction of ESG violators from MSCI-linked ETFs
Halves removal time to 45 days at most from 90 days
11:50, 9 March 2023People also watch
Still looking for a broker you can trust?
Join the 500.000+ traders worldwide that chose to trade with Capital.com